Royal Brompton Hospital

Shockwave Reducer Demonstrates Consistent, Positive Results in ‘Real-World’ Study

Retrieved on: 
Monday, April 8, 2024
Observational study, Cardiovascular disease, University Medical Center, Patient, Angina, Șaeș, CCS, American College, University Medical Center Utrecht, DRS, Royal Brompton Hospital, MACE, Pharmaceutical industry

These findings confirm the positive, ‘real-world’ outcomes of Shockwave Reducer, a novel technology for the treatment of refractory angina.

Key Points: 
  • These findings confirm the positive, ‘real-world’ outcomes of Shockwave Reducer, a novel technology for the treatment of refractory angina.
  • Results were presented earlier today at the 73rd Annual Scientific Sessions of the American College of Cardiology in Atlanta, GA.
    REDUCER-I is a post-market, multi-center, observational study designed to collect long-term outcomes on Shockwave Reducer in a large, ‘real-world’ population of 400 patients.
  • “Results from the REDUCER-I study continue to demonstrate the safety and effectiveness of Shockwave Coronary Sinus Reducer as a novel therapy for refractory angina,” said Dr. Verheye.
  • Results from COSIRA-II are intended to support the regulatory filing for US FDA approval of Shockwave Reducer.

Data from Brainomix's Collaboration with AstraZeneca Shows its AI-Powered e-Lung Better Identifies Lung Fibrosis Patients at Risk of Decline

Retrieved on: 
Wednesday, March 27, 2024
AJRCCM, Medical research, ILD, AstraZeneca, ATS, Survival, Data science, Critical Care Medicine (journal), Partnership, Risk, Boehringer Ingelheim, Royal Brompton Hospital, Patient, American Journal, Lung, WRVS, Biopharmaceutical, Biomarker, Vital capacity, American Thoracic Society, Idiopathic pulmonary fibrosis, IPF, Clinical trial, Tralokinumab, Idiopathic disease, FVC

The study was an analysis of AstraZeneca's Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF).

Key Points: 
  • The study was an analysis of AstraZeneca's Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF).
  • The patient data from the trial was processed with Brainomix's e-Lung tool.
  • The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
  • WRVS was also able to predict both short- and long-term outcomes of the patients, including lung function decline and survival.

Data from Brainomix's Collaboration with AstraZeneca Shows its AI-Powered e-Lung Better Identifies Lung Fibrosis Patients at Risk of Decline

Retrieved on: 
Wednesday, March 27, 2024
AJRCCM, Medical research, ILD, AstraZeneca, ATS, Survival, Data science, Critical Care Medicine (journal), Partnership, Risk, Boehringer Ingelheim, Royal Brompton Hospital, Patient, American Journal, Lung, WRVS, Biopharmaceutical, Biomarker, Vital capacity, American Thoracic Society, Idiopathic pulmonary fibrosis, IPF, Clinical trial, Tralokinumab, Idiopathic disease, FVC

The study was an analysis of AstraZeneca's Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF).

Key Points: 
  • The study was an analysis of AstraZeneca's Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF).
  • The patient data from the trial was processed with Brainomix's e-Lung tool.
  • The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
  • WRVS was also able to predict both short- and long-term outcomes of the patients, including lung function decline and survival.

Angany announces First-in-Human Clinical Study on ANG-101, a Vaccine Candidate to Treat Cat Allergy

Retrieved on: 
Thursday, October 5, 2023
Medicines and Healthcare products Regulatory Agency, HOPE, Hope, Vaccine, Section, Imperial College London, Cat, Allergy, Trial of the century, Royal Brompton Hospital, Risk, Animal, Immunoglobulin G, Safety, Medication, Clinical trial, Fel, MHRA, Human, Patient

The Royal Brompton Hospital, in London, begins Clinical Trial of Angany's Vaccine Candidate to treat Cat Allergy.

Key Points: 
  • The Royal Brompton Hospital, in London, begins Clinical Trial of Angany's Vaccine Candidate to treat Cat Allergy.
  • QUEBEC CITY, Oct. 5, 2023 /CNW/ - Angany Inc., announces that it has received clearance (Notice of Acceptance) from MHRA (Medicines and Healthcare Products Regulatory Agency) for the first clinical study to be conducted on its vaccine candidate ANG-101 to treat human allergy to cats.
  • Angany's ANG-101 is a therapeutic vaccine that provides a disruptive disease-modifying approach for the treatment of cat allergy.
  • We have named this clinical study "HOPE" as this important milestone in Angany's vaccine development program should raise new hope for millions of people affected by allergy worldwide.

Brainomix Partners with TIPAL Trial to Assess Its Novel IPF Biomarker in Lung Disease

Retrieved on: 
Friday, September 8, 2023
Social work, CT, Idiopathic disease, Idiopathic pulmonary fibrosis, Oxford, National Institute of Health Research and Development (Indonesia), NNUH, Scar, ILD, Public, FVC, Lansoprazole, Norfolk and Norwich University Hospital, Lung, Government, Fibrosis, Department of Health and Social Care, Vital capacity, High-resolution scheme, Patient, Spirometry, NHS foundation trust, Heartburn, WRV, NIHR, Diagnosis, AI, IPF, Royal Brompton Hospital, Medical imaging

OXFORD, England, Sept. 8, 2023 /PRNewswire/ -- Brainomix announced today that they will be partnering with the TIPAL trial group to run a sub-study to assess the efficacy of its groundbreaking e-Lung platform. The TIPAL trial, funded by the National Institute of Health Research (NIHR) and sponsored by the Norfolk and Norwich University Hospitals (NNUH) NHS Foundation Trust, is a placebo-controlled 52-week multi-centre study that is evaluating the impact of lansoprazole – a commonly prescribed medication for indigestion, heartburn and acid reflux – on patients with a confirmed diagnosis of Idiopathic Pulmonary Fibrosis (IPF). IPF is a condition marked by relentless decline in lung function, but with a variable disease trajectory.

Key Points: 
  • OXFORD, England, Sept. 8, 2023 /PRNewswire/ -- Brainomix announced today that they will be partnering with the TIPAL trial group to run a sub-study to assess the efficacy of its groundbreaking e-Lung platform.
  • IPF is a condition marked by relentless decline in lung function, but with a variable disease trajectory.
  • The 298 patients expected to be enrolled in the trial will perform home spirometry tests to measure their forced vital capacity (FVC).
  • Professor Andrew Wilson, TIPAL Chief Investigator, said "It is great to have the chance to incorporate the cutting-edge CT scanning technology developed by Brainomix into the TIPAL study.

Heart Failure start-up, Acorai, embarks on the next vital stage towards regulatory approval

Retrieved on: 
Wednesday, August 16, 2023
Well, Duke University, Royal Brompton and Harefield NHS Foundation Trust, Partnership, De novo, Heart failure, Therapy, Sahlgrenska University Hospital, Prevalence, Health care, MLG, Harefield Hospital, Quality of life, Intracardiac injection, Oct, History, Teaching hospital, TCT, Duke University School of Medicine, Royal Brompton Hospital, Vital signs, Patient, Machine learning, Rigshospitalet, Algorithm, Pedigree, Mid America Heart Institute, Entrepreneurship, Coronary artery disease, FDA, City centre, Health, ICPM, Luke the Evangelist, St Luke's, Software, Medical device, Pharmaceutical industry, Kansas City metropolitan area

Acorai was designated as a breakthrough device by the US FDA in August 2023 and they aim to submit their heart monitor for regulatory approval to the FDA and CE-marking in 2024.

Key Points: 
  • Acorai was designated as a breakthrough device by the US FDA in August 2023 and they aim to submit their heart monitor for regulatory approval to the FDA and CE-marking in 2024.
  • Acorai is developing a first-of-its-kind, scalable medical device for non-invasive intracardiac pressure monitoring to improve heart failure management for more than 64 million patients worldwide.
  • Dr. Dar is a cardiologist specializing in heart failure and leads the advanced heart failure, heart transplant, and mechanical circulatory support research programme at Harefield Hospital.
  • We look forward to collaborating with Acorai, whose heart monitor may have the potential to 'change the game' in diagnostics, monitoring, and treatment of patients with heart failure."

Heart Failure start-up, Acorai, embarks on the next vital stage towards regulatory approval

Retrieved on: 
Wednesday, August 16, 2023
Well, Duke University, Royal Brompton and Harefield NHS Foundation Trust, Partnership, De novo, Heart failure, Therapy, Sahlgrenska University Hospital, Prevalence, Health care, MLG, Harefield Hospital, Quality of life, Intracardiac injection, Oct, History, Teaching hospital, TCT, Duke University School of Medicine, Royal Brompton Hospital, Vital signs, Patient, Machine learning, Rigshospitalet, Algorithm, Pedigree, Mid America Heart Institute, Entrepreneurship, Coronary artery disease, FDA, City centre, Health, ICPM, Luke the Evangelist, St Luke's, Software, Medical device, Pharmaceutical industry, Kansas City metropolitan area

Acorai was designated as a breakthrough device by the US FDA in August 2023 and they aim to submit their heart monitor for regulatory approval to the FDA and CE-marking in 2024.

Key Points: 
  • Acorai was designated as a breakthrough device by the US FDA in August 2023 and they aim to submit their heart monitor for regulatory approval to the FDA and CE-marking in 2024.
  • Acorai is developing a first-of-its-kind, scalable medical device for non-invasive intracardiac pressure monitoring to improve heart failure management for more than 64 million patients worldwide.
  • Dr. Dar is a cardiologist specializing in heart failure and leads the advanced heart failure, heart transplant, and mechanical circulatory support research programme at Harefield Hospital.
  • We look forward to collaborating with Acorai, whose heart monitor may have the potential to 'change the game' in diagnostics, monitoring, and treatment of patients with heart failure."

Shockwave Medical Launches New Coronary IVL Catheter Internationally and Enrolls First Patient in All-Female Empower Study

Retrieved on: 
Monday, May 15, 2023
Percutaneous coronary intervention, Male, Royal Brompton Hospital, Shock wave, Heart, C2, Section, Cardiovascular disease, Doctor of Philosophy, De novo, Calcium, IVL, Yale School of Medicine, Trial of the century, MD, Patient, St. Francis Hospital, Hospital, Coronary artery disease, Female, EMPOWER, Pharmaceutical industry, Nursing

SANTA CLARA, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today announced the full commercial availability of the Shockwave C2+ Coronary Intravascular Lithotripsy (IVL) Catheter to treat severely calcified coronary artery disease in select international markets. Shockwave C2+ provides 50 percent more pulses per catheter than Shockwave C2 and is optimally designed to treat longer calcified lesions and more challenging eccentric and nodular calcium.

Key Points: 
  • Shockwave C2+ provides 50 percent more pulses per catheter than Shockwave C2 and is optimally designed to treat longer calcified lesions and more challenging eccentric and nodular calcium.
  • The first patient was enrolled by Richard A. Shlofmitz, MD, Chairman, Department of Cardiology, St. Francis Hospital in Roslyn, New York.
  • The study’s European lead is Nieves Gonzalo, MD, PhD, Consultant Interventional Cardiologist at Hospital Clinico San Carlos in Madrid, Spain.
  • Shockwave C2+ is commercially available for the treatment of de novo coronary artery disease in Europe and select other geographies.

ReCode Therapeutics Appoints John G. Matthews, MBBS, MRCP, Ph.D., as Senior Vice President, Clinical Development

Retrieved on: 
Monday, April 17, 2023
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, 23andMe, GSK plc, Royal Brompton Hospital, Asthma, Drug development, MBBS, Therapy, SORT, Doctor of Philosophy, Bias, MBA, Recode, Inflammation, Messenger, Pulmonology, Novartis, Lane, Patient, Respiratory disease, Cystic fibrosis, Hospital, LNP, Biomarker, Pharmacology, Imperial College London, MRCP, Disease, Medical device, Pharmaceutical industry, Genentech

ReCode Therapeutics , a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today the appointment of John G. Matthews, MBBS, MRCP, Ph.D., as senior vice president of clinical development.

Key Points: 
  • ReCode Therapeutics , a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today the appointment of John G. Matthews, MBBS, MRCP, Ph.D., as senior vice president of clinical development.
  • Dr. Matthews will oversee clinical development planning and strategy.
  • “We are delighted to welcome Dr. Matthews to build and lead our clinical team,” said Shehnaaz Suliman, M.D., MBA, M.Phil., chief executive officer, ReCode Therapeutics.
  • He spent the previous ten years at Genentech, a subsidiary of Roche, in leadership roles including senior group medical director.

LifeMD Appoints Dr. Joan LaRovere to its Board of Directors

Retrieved on: 
Friday, February 10, 2023
Machine learning, Entrepreneurship, MBA, Assistant, Environmental studies, Martin Trust Center for MIT Entrepreneurship, MIT Sloan School of Management, Pediatrics, Hospital, University of St Andrews School of Medicine, Harvard University, The Co Founder, Imperial College School of Medicine, Harvard Medical School, Virtu Foundation, Delhi Sikh Gurdwara Management Committee, First Nations in Ontario, United Nations, Artificial intelligence, Royal Brompton Hospital, Health care, LFMD, Innovation, Faculty, Boston, Pediatric intensive care unit, Columbia University, University, Management, Science, Genetics, Medicine

NEW YORK, Feb. 10, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced the appointment of Dr. Joan LaRovere to its Board of Directors.

Key Points: 
  • NEW YORK, Feb. 10, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced the appointment of Dr. Joan LaRovere to its Board of Directors.
  • With Dr. LaRovere’s appointment, LifeMD’s Board will comprise nine directors, seven of whom are independent.
  • “We are pleased to welcome Dr. LaRovere to the LifeMD Board,” said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD.
  • I believe that LifeMD has built a technology platform and affiliated medical group that will be a driving force in the next chapter of technology-enabled care in the United States and maybe beyond,” said Dr. Joan LaRovere.